TY - JOUR
T1 - The treatment of cognitive impairment in Alzheimer's disease
T2 - Beyond the cholinergic approach
AU - Davidson, M.
AU - Stern, R. G.
PY - 1991
Y1 - 1991
N2 - Despite the well-founded rationale for the use of cholinomimetic and monoaminergic agents in the treatment of Alzheimer's disease, thus far, these strategies have only led to modest results. None of the drugs assessed to date have been shown to improve cognitive function to a clinically significant degree in patients with Alzheimer's disease. Some agents have produced mild improvements on specific tests, whereas others seem to slow down the progression of the disease. This article provides a brief overview of the current trends in the treatment of cognitive dysfunction in Alzheimer's disease.
AB - Despite the well-founded rationale for the use of cholinomimetic and monoaminergic agents in the treatment of Alzheimer's disease, thus far, these strategies have only led to modest results. None of the drugs assessed to date have been shown to improve cognitive function to a clinically significant degree in patients with Alzheimer's disease. Some agents have produced mild improvements on specific tests, whereas others seem to slow down the progression of the disease. This article provides a brief overview of the current trends in the treatment of cognitive dysfunction in Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=0025909841&partnerID=8YFLogxK
U2 - 10.1016/s0193-953x(18)30318-6
DO - 10.1016/s0193-953x(18)30318-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:0025909841
SN - 0193-953X
VL - 14
SP - 461
EP - 482
JO - Psychiatric Clinics of North America
JF - Psychiatric Clinics of North America
IS - 2
ER -